| P50 | author | Miguel Martin | Q56550967 |
| | Sara López-Tarruella | Q57063863 |
| P2093 | author name string | Miguel Martín | |
| | Sara López-Tarruella | |
| P2860 | cites work | Taxanes for adjuvant treatment of early breast cancer | Q24242987 |
| | Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 |
| | Clinical application of the 70-gene profile: the MINDACT trial | Q28267891 |
| | Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 |
| | Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 |
| | Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. | Q31960126 |
| | Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. | Q32107791 |
| | Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial | Q33724456 |
| | Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer | Q34162335 |
| | Population-based validation of the prognostic model ADJUVANT! for early breast cancer | Q34412284 |
| | Effect of screening and adjuvant therapy on mortality from breast cancer | Q34463105 |
| | Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer | Q34496969 |
| | Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast canc | Q34534314 |
| | Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer | Q34601123 |
| | Predictive factors for response to docetaxel in human breast cancers | Q36521963 |
| | Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. | Q36901398 |
| | Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer. | Q36965437 |
| | Markers predicting clinical benefit in breast cancer from microtubule-targeting agents | Q37033609 |
| | Development of the 21-gene assay and its application in clinical practice and clinical trials | Q37079600 |
| | Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197 | Q37125089 |
| | Weekly paclitaxel in the adjuvant treatment of breast cancer. | Q37346811 |
| | Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis | Q39945691 |
| | Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation | Q44174541 |
| | Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial | Q44276675 |
| | Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. | Q44362100 |
| | Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience | Q44381560 |
| | Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer | Q44902909 |
| | Patterns of relapse and survival following radical mastectomy.Analysis of 716 consecutive patients | Q46012628 |
| | Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. | Q46127853 |
| | Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study | Q46463193 |
| | Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. | Q46493659 |
| | Adjuvant docetaxel for node-positive breast cancer | Q46522790 |
| | Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide | Q46551686 |
| | Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. | Q46570397 |
| | Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. | Q46573303 |
| | Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group | Q46691182 |
| | retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: | Q46761542 |
| | Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. | Q46817262 |
| | Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study | Q46825153 |
| | Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials | Q46828225 |
| | 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 |
| | HER2 and responsiveness of breast cancer to adjuvant chemotherapy. | Q54600960 |
| | HER2 and Response to Paclitaxel in Node-Positive Breast Cancer | Q57578418 |
| | Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu | Q57578575 |
| | Benefit of taxanes as adjuvant chemotherapy for early breast cancer | Q61899631 |
| | Congestive Heart Failure in Older Women Treated With Adjuvant Anthracycline Chemotherapy for Breast Cancer | Q63365933 |
| | Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial | Q66829419 |
| | 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings | Q66903287 |
| | Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results | Q68536818 |
| | Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up | Q72596355 |
| | Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group | Q77347398 |
| | HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials | Q80408348 |
| | Can biology trump anatomy? Do all node-positive patients with breast cancer need chemotherapy? | Q80495845 |
| | Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27 | Q83137320 |
| | Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401 | Q83305244 |
| P433 | issue | 2 | |
| P921 | main subject | systemic therapy | Q1929812 |
| | antineoplastic | Q2853144 |
| | chemotherapy regimen | Q5090632 |
| | breast neoplasm | Q23929670 |
| P304 | page(s) | 204 | |
| P577 | publication date | 2009-03-19 | |
| P1433 | published in | Breast Cancer Research | Q2208481 |
| P1476 | title | Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer | |
| P478 | volume | 11 | |